Although drug-induced transient myopia has been reported to be caused by the use of several drugs, it is very rare and the causes are still uncertain. A considerable literature has accumulated relating the occasional occurrence of myopia in patients receiving carbonic anhydrase inhibitors, especially acetazolamide. However the authors could not find any literature concerning transient myopia induced by dichlorphenamide. The authors reporthed here a case of transient myopia after dichlorphenamide in a patient with serous detachment of the macula with a review of the literatures.
Acetazolamide ; Carbonic Anhydrase Inhibitors ; Dichlorphenamide* ; Humans ; Myopia*

Although drug-induced transient myopia has been reported to be caused by the use of several drugs, it is very rare and the causes are still uncertain. A considerable literature has accumulated relating the occasional occurrence of myopia in patients receiving carbonic anhydrase inhibitors, especially acetazolamide. However the authors could not find any literature concerning transient myopia induced by dichlorphenamide. The authors reporthed here a case of transient myopia after dichlorphenamide in a patient with serous detachment of the macula with a review of the literatures.
Acetazolamide ; Carbonic Anhydrase Inhibitors ; Dichlorphenamide* ; Humans ; Myopia*

PURPOSE: This study is to determine whether topical dorzolamide and systemic acetazolamide have an additive effect on the changes in intraocular pressure (IOP) in patients with open angle glaucoma. METHODS: Twenty eyes of 10 patients being treated with only acetazolamide (Group 1) and 20 eyes of 10 patients being treated with only dorzolamide (Group 2) were included in this study. Dorzolamide was additionally applied three times a day to Group 1 and acetazolamide 250 mg three times a day was additionally given to Group 2. Changes in intraocular pressure and complications due to overdose of carbonic anhydrase inhibitors (CAIs) were checked 1, 2, and 4 weeks after the additional treatment. RESULTS: The IOP was reduced 1.0+/-2.9% (N=20) (p>0.05) from the baseline pressure checked before the additional treatment in Group 1 and 13.2+/-3.6% (N=16) (p<0.01) in Group 2. No significant complication due to CAI usage was observed. CONCLUSIONS: In patients with open angle glaucoma, combination therapy of systemic and topical CAIs was effective only when additional systemic CAI was given to the cases using topical agents.
Acetazolamide* ; Carbonic Anhydrase Inhibitors ; Glaucoma, Open-Angle ; Humans ; Intraocular Pressure*

No abstract available.
Carbonic Anhydrase Inhibitors* ; Haplotypes* ; Humans ; Stevens-Johnson Syndrome*

PURPOSE: To investigate and compare the effects of topical carbonic anhydrase inhibitors on the production and expression of nitric oxide in cultured human trabecular meshwork cells (HTMC). METHODS: Primarily cultured HTMC were exposed to 0, 10, and 100 microM dorzolamide and brinzolamide using serum-deprived media for 3 days. Production of nitric oxide was assessed with Griess assay. Expressions of eNOS mRNA were assessed with RT-PCR. RESULTS: Both dorzolamide and brinzolamide increased the production of nitric oxide eNOS activity (p < 0.05). Dorzolamide had a more potent effect than brinzolamide on the production of nitric oxide and the expression of eNOS mRNA. CONCLUSIONS: Topical carbonic anhydrase inhibitors increased the production of nitric oxide, which was accompanied by increased eNOS activity. Dorzolamide had a more potent effect than brinzolamide on the production of nitric oxide and expression of eNOS mRNA in HTMC. The increased production of nitric oxide by topical carbonic anhydrase inhibitors involves mechanisms other than carbonic anhydrase inhibition.
Carbon* ; Carbonic Anhydrase Inhibitors* ; Carbonic Anhydrases* ; Humans ; Nitric Oxide* ; RNA, Messenger ; Trabecular Meshwork*

Carbonic anhydrase IX (CA IX) is a tumor associated protein which is able to be a potent anticancer target, since it is highly expressed in a multitude of carcinomas, while it is present in a limited number of normal tissues. This review focuses on its role in tumor physiology, the most recent three dimensional structure features of this enzyme which has recently been elucidated. In addition, we present recent advances in the development of small inhibitors able to target CA IX for therapeutic applications.
Antigens, Neoplasm ; metabolism ; Antineoplastic Agents ; chemistry ; therapeutic use ; Carbonic Anhydrase IX ; Carbonic Anhydrase Inhibitors ; chemistry ; therapeutic use ; Carbonic Anhydrases ; metabolism ; Humans ; Neoplasms ; drug therapy ; enzymology

Methazolamide is a carbonic anhydrase inhibitor commonly used for lowering intraocular pressure in glaucoma and other ophthalmologic diseases. Carbonic anhydrase inhibitors are sulfonamide derivatives that are known to cause many adverse side effects, including dermatologic reactions. Recently, Stevens-Johnson syndrome (SJS) associated with methazolamide treatment has been reported in Japanese and Japanese Americans, and it suggested a relationship between genetic background and methazolamide-induced SJS. We report four cases of SJS induced by methazolamide. Methazolamide should be prescribed with caution in patients of Japanese or Korean descent.
Asian Americans ; Asian Continental Ancestry Group ; Carbonic Anhydrase Inhibitors ; Carbonic Anhydrases ; Glaucoma ; Humans ; Intraocular Pressure ; Methazolamide* ; Stevens-Johnson Syndrome*

Brinzolamide and dorzolamide are highly specific topical carbonic anhydrase inhibitors (CAIs). They lower intraocular pressure (IOP) by reducing the rate of aqueous humour formation without serious side effects. Although systemic CAIs are the most potent medications for lowering intraocular pressure for conditions with ocular hypertension, many cases with adverse systemic reactions have been reported, including Stevens-Johnson syndrome (SJS) and Toxic epidermal necrolysis (TEN). Here, we report 2 cases of TEN that were associated with topical CAIs rather than systemic CAIs.
Carbon ; Carbonic Anhydrase Inhibitors ; Carbonic Anhydrases ; Epidermal Necrolysis, Toxic ; Intraocular Pressure ; Ocular Hypertension ; Stevens-Johnson Syndrome ; Sulfonamides ; Thiazines ; Thiophenes

Alteration of the chemical composition of aqueous humor may be closely related to the occurrence of glaucoma. Comparison of chemical composition of aqueous humor in glaucoma patients with that of the normal eyes is thought to be helpful in searching the pathogenesis and treatment modality of glaucoma. Concentration of 8 chemical components in the aqueous humor of cataract eyes as well as glaucoma eyes was analyzed and the differences between the two groups were searched by the authors. Subjects were 47 eyes of 47 cataract patients and 35 eyes of 32 glaucoma patients. During the operation 0.1-0.2cc of aqueous humor was collected by anterior chamber paracentesis and 10cc of blood was also drawn. In cataract patients, the mean values were Na+;145.2, K+;4.0, Cl-;123.7, HCO3-; 22.9 mEq/l, Ca++;6.6, Mg++;1.7, glucose; 48.2 mg/100 ml and ascorbic acid; 245.5 microgram/ml. In glaucoma patients, the mean values were Na+;142.1, K+;4.0, Cl-;126.0, HCO3-;17.6 mEq/I, Ca++;6.3, Mg++;1.9, glucose; 59.4 mg/100 ml and ascorbic acid; 227.5 microgram/ml. Aqueous glucose concentration was 55% of blood glucose level, and aqueous ascorbic acid concentration was 62 times higher than that in blood. Regarding the eight components in aqueous humor, no significant difference was found between cataract and glaucoma patients. Lack of significant difference in ascorbic acid levels between the two groups was thought to be due to the use of carbonic anhydrase inhibitors prior to glaucoma surgery.
Anterior Chamber ; Aqueous Humor* ; Ascorbic Acid ; Blood Glucose ; Carbonic Anhydrase Inhibitors ; Cataract* ; Glaucoma* ; Glucose ; Humans ; Paracentesis

OBJECTIVETo explore the effects of different doses of P-8 in increasing the Hypoxia tolerance of mice and the mechanisms involved.

METHODSThe health mice were placed into the oxygen deficit bottles and measured the survival time in the condition of hypoxia. The male mice were put into the ladder cage, then placed them into the hypobaric champer to determine the survival time of mice with decompression hypoxia (min). We observed the activity changes of the mice's organization carbonic anhydrase II (CAII). By using the drug in prophylaxis, we investigated the effects of carbonic anhydrase target-based inhibitors P-8 for improving the hypoxia tolerance.

RESULTS(1) In improving the endurance of mice in the condition of hypoxia, the survival time of 6.25 mg/(kg x d) and more doses of P-8 groups were (27.38 +/- 4.63, 29.53 +/- 4.43, 29.67 +/- 7.28, 31.55 +/- 6.34, 32.45 +/- 6.65, 36.81 +/- 7.24 and 35.41 +/- 4.20) min, compared with the control group (22.90 +/- 3.19) min , the survival time significantly prolonged (P < 0.05, P < 0.01); compared to the same dose of acetazolamide groups (24.54 +/- 3.17, 22.70 +/- 3.04, 22.67 +/- 2.99, 23.93 +/- 0.96, 27.87 +/- 5.06, 30.79 +/- 5.12 and 35.14 +/- 6.46) min, the survival time significantly prolonged; P-8 groups and Acetazolamide's minimum effective dose were 6.25 and 100 mg/(kg x d), the potency of P-8 is 16 times Acetazolamide. (2) In improving the endurance of mice in the condition of hypoxia, the survival time of middle and high doses of P-8 groups [(24.82 +/- -3.92, 28.27 +/- 5.89) min] were significantly longer than those in control group [(21.96 2.51) min, P < 0.05]; compared with the acetazolamide (23.11 +/- 3.71) min, the survival time of high dose of P-8 group was significantly prolonged. (3) Compared with the normal control group, P-8 [(25 mg/(kg x d), 50 mg/(kg x d), 100 mg/(kg x d), 200 mg/(kg x d)] dose groups inhibited the activity of carbonic anhydrase II (CAII) in the renal (P < 0.05, P < 0.01); P-8 [100 mg/(kg x d) and 200 mg/(kg x d)] dose group significantly inhibited the activity of carbonic anhydrase II (CA II) in the brain (P < 0.05).

CONCLUSIONP-8 treatment improved the endurance of mice in the condition of hypoxia and worked better than Acetazolamide. The mechanism may be related to the inhibition of carbonic anhydrase organization.

Adaptation, Physiological ; physiology ; Altitude Sickness ; prevention & control ; Animals ; Carbonic Anhydrase Inhibitors ; pharmacology ; therapeutic use ; Hypoxia ; physiopathology ; Male ; Mice